stoxline Quote Chart Rank Option Currency Glossary
  
Galapagos NV (GLPG)
26.69  0.15 (0.57%)    02-19 16:00
Open: 26.53
High: 26.99
Volume: 252,377
  
Pre. Close: 26.54
Low: 26.52
Market Cap: 1,759(M)
Technical analysis
2025-02-19 3:52:18 PM
Short term     
Mid term     
Targets 6-month :  32.09 1-year :  37.48
Resists First :  27.47 Second :  32.09
Pivot price 23.9
Supports First :  24.31 Second :  22.36
MAs MA(5) :  25.83 MA(20) :  23.84
MA(100) :  26.87 MA(250) :  28.15
MACD MACD :  0.1 Signal :  -0.5
%K %D K(14,3) :  87.5 D(3) :  92.5
RSI RSI(14): 71.1
52-week High :  39.9 Low :  22.36
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ GLPG ] has closed below upper band by 0.6%. Bollinger Bands are 70.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 27.51 - 27.62 27.62 - 27.71
Low: 25.99 - 26.13 26.13 - 26.24
Close: 26.31 - 26.53 26.53 - 26.71
Company Description

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Headline News

Wed, 19 Feb 2025
Short Interest in Galapagos NV (NASDAQ:GLPG) Expands By 8.2% - MarketBeat

Wed, 19 Feb 2025
Galapagos projects 2026 pivotal trials for GLPG5101 following FDA clearance - MSN

Mon, 17 Feb 2025
Analysts Just Shaved Their Galapagos NV (AMS:GLPG) Forecasts Dramatically - Simply Wall St

Mon, 17 Feb 2025
Galapagos receives transparency notification and 13D filing from Tang Capital - TradingView

Mon, 17 Feb 2025
Trend Tracker for (GLPG) - news.stocktradersdaily.com

Sun, 16 Feb 2025
Galapagos NV Earnings Call: Strategic Moves Amid Challenges - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 66 (M)
Shares Float 44 (M)
Held by Insiders 0 (%)
Held by Institutions 47.8 (%)
Shares Short 1,710 (K)
Shares Short P.Month 1,620 (K)
Stock Financials
EPS -0.02
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 43.95
Profit Margin 26.8 %
Operating Margin -83.1 %
Return on Assets (ttm) -2.8 %
Return on Equity (ttm) -0.1 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) -1.44
Sales Per Share 4.18
EBITDA (p.s.) -2.33
Qtrly Earnings Growth 0 %
Operating Cash Flow -320 (M)
Levered Free Cash Flow -301 (M)
Stock Valuations
PE Ratio -1336.5
PEG Ratio 0
Price to Book value 0.6
Price to Sales 6.39
Price to Cash Flow -5.51
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android